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The heterotrimeric globular head (gC1q) domain of human C1q is made up of the 
C-terminal ends of the three individual chains, ghA, ghB, and ghC. A candidate 
receptor for the gC1q domain is a multi-functional pattern recognition protein, gC1qR. 
Since understanding of gC1qR and gC1q interaction could provide an insight into the 
pleiotropic functions of gC1qR, this study was undertaken to identify the gC1qR-binding 
site on the gC1q domain, using the recombinant ghA, ghB, and ghC modules and their 
substitution mutants. Our results show that ghA, ghB, and ghC modules can interact 
with gC1qR independently, thus reinforcing the notion of modularity within the gC1q 
domain of human C1q. Mutational analysis revealed that while Arg162 in the ghA module 
is central to interaction between gC1qR and C1q, a single amino acid substitution 
(arginine to glutamate) in residue 114 of the ghB module resulted in enhanced binding. 
Expression of gC1qR and C1q in adherent monocytes with or without pro-inflammatory 
stimuli was also analyzed by qPCR; it showed an autocrine/paracrine basis of C1q and 
gC1qR interaction. Microscopic studies revealed that C1q and gC1qR are colocalized 
on PBMCs. Cell proliferation assays indicated that ghA, ghB, and ghC modules were 
able to attenuate phytohemagglutinin-stimulated proliferation of PBMCs. Addition of 
gC1qR had an additive effect on the anti-proliferative effect of globular head modules. 
In summary, our results identify residues involved in C1q-gC1qR interaction and explain, 
to a certain level, their involvement on the immune cell surface, which is relevant for 
C1q-induced functions including inflammation, infection, and immunity.
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inTrODUcTiOn
C1q is the first subcomponent of the classical pathway of the complement system that links innate and 
adaptive immunity by virtue of recognizing IgG and IgM in the immune complexes (1). Structurally, 
human C1q (460 kDa) is made up of 18 polypeptides, i.e., 6A, 6B, and 6C chains. Each chain has 
a short N-terminal region, a collagen-like region (CLR), and a C-terminal globular head (gC1q) 
domain (2). A combination of interchain disulfide bond formation and triple-helical CLR gives 
rise to an ABC–CBA structural subunit. Three of these subunits associate to yield the hexameric 
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C1q molecule. The gC1q domain is a hetrotrimeric structure 
composed of C-terminal halves of A, B, and C chains. C1q is able 
to bind to an array of self, non-self, and altered-self ligands (3–7) 
via its gC1q domain (8). This ligand-binding versatility of C1q is 
offered by the modular organization of the individual globular 
head (gh) modules, ghA, ghB, and ghC, which are considered 
structurally and functionally independent (9–12).
A candidate receptor that binds to the gC1q domain of human 
C1q, called gC1qR (33 kDa), is a highly acidic, multi-ligand bind-
ing, and multi-functional protein. In addition to its role in the 
complement system, gC1qR is also involved in blood clotting via 
interaction with thrombin and vitronectin (13). Furthermore, as 
a high affinity receptor for high molecular weight kininogen and 
FXII, gC1qR present on the endothelial cells is able to serve as a 
major platform for the activation of the kinin/kallikrein, leading 
to the generation of the vasoactive peptide, bradykinin (14, 15).
Although the gC1q–gC1qR interaction has been described 
previously (16), the complementary binding sites and the precise 
nature of interaction remain to be fully established. The major 
gC1q-binding site on gC1qR has been shown to be located on 
residues 76–93 based on peptides studies (17). The availability 
of the recombinant individual gh modules, ghA, ghB, and ghC, 
which represent globular region of A, B, and C chains, respectively, 
without collagen region of C1q (18) has given us the opportunity 
to examine the gC1q–gC1qR interaction more closely. With 
respect to the structure/function relationship within the gC1q 
domain (19, 20), it is now known that ghA, ghB, and ghC are 
functionally independent modules. The modular organization of 
the gC1q domain offers C1q, the versatility required for binding 
to a range of self and non-self ligands. This is evident in the case 
of the HIV-1 gp41 peptide 601–613, which preferentially binds 
to ghA (20), and the β-amyloid peptide specifically interacting 
with ghB (20).
The crystal structure of gC1qR has revealed three monomers 
held together to form a trimer (21). Each monomer consists of 
seven anti-parallel β strands filled by an N-terminal and two 
C-terminal α helices. gC1qR has a distinct charge distribution, 
with the “solution face” of its “donut” shaped structure that is 
highly negatively charged and exposed to the plasma, while the 
reverse side or “membrane face” is neutral or basic (17). The C1q 
binding site, residues 76–93, is exposed only on the highly charged 
solution face (17). Since the C1q binding site on gC1qR has been 
identified, we sought to identify the complementary residues on 
the gC1q domain that are involved in the gC1q–gC1qR interac-
tion. Previous studies have highlighted ArgB114 and ArgB129 of the 
B chain to be central in the C1q–IgG interaction (22). It has also 
been shown that C1q binding to gC1qR on platelets (23) and 
endothelial cells (24) induces complement activation independ-
ent of IgG. Furthermore, although gC1qR has been shown to 
bind to the gC1q domain of C1q, its physiological relevance still 
remains to be established.
Here, we have examined the interaction of recombinant forms 
of ghA, ghB, and ghC modules with gC1qR. We also used single 
residue substitution mutants for ghA, ghB, and ghC (19, 20, 22) 
that allowed us to identify residues on the gC1q domain that 
participate in the C1q–gC1qR interaction. A number of substitu-
tion mutants: ghA-R162A, ghA-R162E, ghB-R114A, ghB-R114Q, 
ghB-R163E, ghB-R163A, ghB-H117D, ghB-R129A, ghB-R129E, 
ghB-T175L, ghC-R156E, ghC-L170E, and ghC-H101A were 
tested for their interaction with gC1qR. The functional characteri-
zation of the point mutants identified an important role of Arg162 
of ghA and Arg114 of ghB in the structure–function relationship 
involving C1q and gC1qR.
It is known that at sites of inflammation, adherent monocytes 
start to overexpress C1q. Thus, we performed a series of qPCR 
experiments to assess whether gC1qR expression was concomi-
tant with C1q in adherent monocytes. gC1qR was upregulated, 
together with C1q on adherent monocytes, suggesting that both 
the ligand and the receptor are required under inflammatory con-
ditions. The previously reported C1q-mediated anti-proliferative 
effect on T cells (25) could be reproduced qualitatively by the 
individual recombinant gh modules, which inhibited phytohe-
magglutinin (PHA)-stimulated proliferation of PBMCs. This 
anti-proliferative effect of gh modules was further enhanced 
by the addition of gC1qR, suggesting that gC1qR, in conjunc-
tion with C1q, can play an important role in modifying cellular 
immune responses.
eXPeriMenTal PrOceDUres
Purification of human c1q
C1q was purified from freshly thawed plasma, as published 
earlier (26). Briefly, plasma was made 5mM EDTA, pH 7.5, 
and centrifuged at 12,000 × g to remove aggregated lipids. The 
plasma was then incubated with non-immune IgG coupled to 
CNBr-activated Sepharose (GE Healthcare, UK) for 1 h at 4°C. 
The plasma was filtered through a sintered glass funnel, and 
C1q bound to IgG–Sepharose was then washed extensively with 
10  mM HEPES, 140  mM NaCl, 0.5  mM EDTA, and pH 7.0. 
C1q was eluted with N-cyclohexyl-3-aminopropanesulfonic 
acid (CAPS) buffer (100 mM CAPS, 1 M NaCl, 0.5 mM EDTA, 
pH  11). The eluted C1q was then passed through a HiTrap 
Protein G column (GE Healthcare) to remove IgG contaminants 
and dialyzed against the washing buffer.
expression and Purification of Wild-type 
gha, ghB, ghc, and substitution Mutants
The recombinant gh modules ghA, ghB, ghC, and their respec-
tive substitution mutants, were expressed in Escherichia coli BL21 
fused to maltose-binding protein (MBP) in their monomeric 
forms (18). Bacterial cells were grown in 200 ml Luria–Bertani 
(LB) medium containing ampicillin (100 μg/ml) at 37°C on a 
shaker. Once grown to an OD600 of 0.6, the bacterial cells were 
induced with 0.4mM isopropyl β-d-thiogalactoside (IPTG) for 
3 h and pelleted via centrifugation (4500 rpm for 15 min). The cell 
pellet was suspended in 25 ml of lysis buffer [20 mM Tris–HCl pH 
8.0, 0.5 M NaCl, 1 mM EDTA, 0.2% v/v Tween 20, 5% glycerol, 
0.1 mM phenylmethylsulfonyl fluoride (PMSF), and 100 μg/ml 
lysozyme] and incubated at 4°C for 1 h on a rotatory shaker. The 
cells were then sonicated (SoniPrep 150) at 60 Hz for 30 s with 
2 min interval for 10 cycles. After centrifugation (13,000 rpm for 
15  min), the supernatant was collected and diluted fivefold in 
buffer I (20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 0.2% Tween 
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20, 1 mM EDTA, and 5% v/v glycerol) and passed through an 
amylose resin 15  ml bed column (New England Biolabs). The 
column was previously washed with three bed volumes of buffer 
I followed by buffer II (buffer I without Tween 20). The protein 
was then eluted in 1 ml fractions with 10 mM maltose in buffer II.
cloning, expression, and Purification of 
human gc1qr
Recombinant mature gC1qR (residues 74–282) (27) was 
expressed in E. coli BL21 (λDE3) (Life Technologies). Bacterial 
cells were grown in 250 ml of LB medium at 37°C until an OD600 
of 0.6 was reached and protein expression was induced with 
0.5 mM IPTG. Following another 3 h incubation on a shaker, 
bacterial culture was spun down (4500 rpm, 15 min). The cell 
pellet was treated with lysis buffer (20 mM Tris pH 8.0, 0.5 M 
NaCl, 1 mM EDTA, 0.2% v/v Tween, 5% v/v glycerol, and 100 μg/
ml lysozyme) and incubated for 1 h at 4°C with mild shaking. 
The resulting cell lysate was sonicated, as described above for gh 
modules. The sonicate was spun down at 13,000 rpm for 15 min, 
and the collected supernatant was dialyzed for 2  h against 
20 mM Tris–HCl, pH 7.5. The dialyzed protein was subjected to 
an ion exchange chromatography using a Q-Sepharose column 
(Sigma). gC1qR was step-eluted at 0.45 M NaCl. Although we did 
not determine the oligomeric state of the recombinant gC1qR, 
it is likely to be a trimeric structure, based on the crystallization 
studies (21).
The purified fractions were passed through Pierce™ High 
Capacity Endotoxin Removal Resin (Thermo Fisher) to remove 
lipopolysaccharides (LPSs). Endotoxin levels in the protein 
preparations were determined using the QCL-1000 Limulus 
amebocyte lysate system (BioWhittaker Inc., USA). The assay was 
linear over a range of 0.1–1.0 EU/ml (10 EU = 1 ng of endotoxin) 
and the amount of endotoxin present in the preparations was 
estimated to be <4 pg/μg of the recombinant protein.
elisa
Direct binding ELISA was performed to examine the interaction 
of C1q and gh modules with gC1qR. Microtiter wells (Maxisorp, 
Nunc) were coated with 1 μg of gC1qR (in 100 μl) in carbonate/
bicarbonate buffer, pH 9.6, and left overnight at 4°C. Unbound 
proteins were removed and the wells were blocked with 2% w/v 
BSA in PBS for 2 h at 37°C. The plate was then washed three times 
with PBS + 0.05% Tween 20, and then different concentrations 
(2.5, 1.25, 0.625, and 0.312 μg/well) of ghA, ghB, or ghC modules 
(MBP as a control protein) were diluted in calcium buffer (50 mM 
Tris–HCl pH 8.0, 100 mM NaCl, and 5 mM CaCl2) and added 
to the wells. The plate was kept first at 37°C for 1  h and then 
at 4°C for another hour. Following further washes, the bound 
protein was detected by anti-MBP monoclonal antibody (Sigma) 
(1:5000 dilution in PBS) and probed with rabbit anti-mouse IgG 
Horseradish peroxidase (HRP; 1:5000; Promega; #W402b) in 
PBS. Color was developed using o-phenylenediamine dihydro-
chloride (OPD) substrate (Thermo-Fisher Scientific) and the 
plate was read at 450  nm using iMark Microplate Absorbance 
reader (Bio-Rad).
Microtiter wells were coated with different concentrations 
of human C1q (5, 2.5, 1.25, and 0.625  μg/well in 100  μl) in 
carbonate/bicarbonate buffer, pH 9.6, and left overnight at 4°C. 
Unbound proteins were removed and the wells were blocked 
with 2% w/v BSA in PBS for 2  h at 37°C. The plate was then 
washed three times with PBS + 0.05% Tween 20, and then the 
wells were incubated with 2.5 μg of gC1qR in calcium buffer 
(50 mM Tris–HCl, pH 8.0, 100 mM NaCl, and 5 mM CaCl2). 
The plate was kept first at 37°C for 1 h and then at 4°C for another 
hour. Following further washes, bound gC1qR was detected by 
anti-gC1qR polyclonal antibody (IgG fraction; 1:5000 dilution), 
followed by Protein A-HRP (1:5000 dilution) conjugate. MBP 
was used as a negative control protein.
Western Blotting
The immunoreactivity of the recombinant gC1qR (10 μg/lane) 
was  assessed by western blotting. Following a 12% v/v SDS-
PAGE gel, the protein was electrophoretically transferred 
onto PDVF membrane, followed by blocking for 1  h at room 
temperature with 5% non-fat milk in PBS. Recombinant human 
gC1qR was probed with rabbit anti-human gC1qR polyclonal 
antibodies (IgG fraction; 500  μg/ml concentration; 1:1000 
dilution) and incubated at 37°C for 1  h. The membrane was 
washed three times in 0.02% PBS–Tween 20, 30 min each and 
probed with Protein A-HRP conjugate (Sigma, 1:1000 dilution 
in PBS) for 1 h at room temperature. Color was developed using 
3,3′-diaminobenzidine (DAB).
Far-western blot was carried out to test the interaction of 
ghA, ghB, ghC, and key substitution mutants with gC1qR. Ten 
micrograms of each protein was run on a SDS-PAGE gel, fol-
lowed by transferring and blocking as described above. Fifteen 
micrograms per milliliter of either the gh’s modules or gC1qR was 
added in 10 ml calcium buffer (20 mM Tris–HCl, pH 7.5, 5 mM 
CaCl2, and 100  mM NaCl) and incubated overnight at 37°C. 
Membranes were washed and probed with either polyclonal anti-
gC1qR or rabbit anti-MBP (Life Technologies, 1:1000) polyclonal 
antibodies which were diluted in 2% w/v non-fat milk powder in 
PBS and incubated for 2 h at 37°C. The blots were developed as 
described above.
Fluorescence Microscopy
The binding of recombinant ghA, ghB, and ghC modules to 
gC1qR was examined microscopically using monocyte-derived 
human macrophages. Human PBMCs were separated from 
human blood from healthy volunteers (with ethical approval 
by the Institutional committee of Brunel University London) 
by Ficoll-paque (GE Healthcare) density gradient method. The 
separated PBMCs were suspended in complete medium (RPMI 
1640, 2mM l-glutamine, 100 μg/ml Penicillin/Streptomycin, and 
10% FCS). The 1 × 106 cells were seeded on 13 mm diameter cover 
slips and incubated for 14 days at 37°C in 5% CO2 incubator.
PBMCs were treated with 10 μg of individual gh modules for 
1 h at 37°C in serum-free medium. MBP (10 μg) was used as a 
negative control protein. Cells were then washed three times with 
PBS, fixed using 4% paraformaldehyde (PFA) for 10 min, and then 
rinsed with PBS three times. The coverslips were permeabilized 
using a buffer containing 20mM HEPES–NaOH pH 7.4, 300mM 
sucrose, 50mM NaCl, 3mM MgCl2, 0.5% Triton X-100, and 10% 
sodium azide for 5 min on ice, and then blocked with 5% FCS 
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in PBS (wash buffer) for 30 min. The slides were then incubated 
with mouse anti-MBP (1:500 dilution in wash buffer) and rabbit 
anti-gC1qR antibodies (1:100 dilution in wash buffer) for 30 min. 
The slides were washed three times in wash buffer, 10 min each, 
and subsequently incubated with secondary antibodies: Alexa 
Fluor 647 conjugated donkey-anti-mouse antibody (Abcam; Cat: 
ab150111) 1:500 dilution in wash buffer and Alexa Fluor 488 
conjugated goat anti-rabbit antibody (Abcam; Cat: ab150077) 
1:500 dilution in wash buffer for 30 min. To stain the nucleus, 
Hoechst 33342 (Invitrogen, Cat: H3570 at 1:10,000 dilution) was 
used. The slides were then washed three times in the wash buffer 
10 min each, mounted using Citifluor anti-fade (Citifluor, UK) 
and observed under a Leica DM4000 Fluorescent microscope 
using Leica Application Suite Software. In the merged images, 
the Alexa Fluor 647 color was set to red.
Quantitative rT-Pcr
Whole blood (50  ml) was taken from healthy volunteers and 
2 units/ml of heparin sodium (product details – PL 29931/015) 
(Wockhardt), was added to prevent blood clotting. Blood was 
then diluted with an equal volume of RPMI 1640. To isolate 
monocytes, blood in RPMI 1640 was separated on a Ficol column 
(Ficol-Plaque Plus, GE healthcare) by centrifugation at 2000 rpm 
for 16  min at room temperature. The top layer was removed 
and PBMCs interphase layer was carefully removed. An equal 
volume of RPMI 1640 was then added and the cells were pelleted 
by centrifugation at 1500 rpm for 10 min at room temperature. 
Cells were then re-suspended in 50  ml of RPMI 1640 and the 
cell concentration was determined using a hemocytometer (total 
yield 7 × 107 cells).
Then, 5 ×  106  cells were added to each tissue culture well 
in a 24-well plate in 5  ml of RPMI 1640 containing 10% FCS, 
100  μg/ml penicillin-streptomycin, and 2  mM l-glutamine, 
and incubated at 37°C with 5% CO2 v/v atmosphere and left to 
adhere. Cells were then harvested at the following time points of 
incubation for adherence: 2 h, 24 h, 48 h, 72 h, 5 days, and 7 days. 
A similar experiment was also set up with the addition of 20 ng/μl 
of LPS (Salmonella typhimurium, Sigma-Aldrich). Adherent cells, 
with or without LPS, from each time point were harvested by 
removing the media from the plate and incubating cells in RPMI 
1640 containing 0.025% trypsin/0.01% EDTA for 5 min at 37°C. 
Cells were removed using a cell scraper and an equal volume of 
RPMI 1640 containing 10% FCS was added to the harvested cells. 
Cells were pelleted by centrifugation at 1500 rpm for 10 min at 
room temperature and stored at −80°C until RNA extraction was 
carried out.
Total RNA was extracted using the GenElute Mammalian 
Total RNA Purification Kit (Sigma-Aldrich). Samples were then 
treated with DNase I (Sigma-Aldrich) to remove any contami-
nating DNA followed by heating at 70°C for 10 min to inactivate 
both DNase I and RNase, and then chilled on ice. The amount 
of total RNA was measured by determining the absorbance 
at 260  nm using the NanoDrop 2000/2000c (Thermo-Fisher 
Scientific) and the purity of the RNA was assessed using the ratio 
of absorbance at 260 and 280 nm. cDNA was synthesized using 
High Capacity RNA to cDNA Kit (Applied Biosystems) using 
2 μg of total RNA.
Primer sequences were designed using the nucleotide Basic 
Local Alignment Search Tool and Primer (BLAST, http://blast.
ncbi.nlm.nih.gov/Blast.cgi). The following primers were used: 
for 18S rRNA gene (endogenous control): forward (5′-ATG 
GCCGTTCTTAGTTGGTG-3′), reverse (5′-CGCTGAGCCAGT 
CAGTGTAG-3′); for C1q C chain gene: forward (5′-CAAA 
GGGCAGAAGGGAGAAC-3′), reverse (5′-ATCTGATCAGGC 
TGTTGGGT-3′); and for gC1qR gene: forward (5′-AACAA 
CAGCATCCCACCAAC-3′), reverse (5′-AGATGTCACTCTCA 
GCCTCG-3′).
PCR was performed on all samples in order to assess the 
quality of cDNA. The qPCR reactions, performed for measur-
ing the expression level of C1q and gC1qR, consisted of 5 μl 
Power SYBR Green MasterMix (Applied Biosystems), 75nM of 
forward and reverse primer, 500 ng template cDNA in a 10 μl 
final volume, using a 7900HT Fast Real-Time PCR System 
(Applied Biosystems). The initial steps were 2  min incubation 
at 50°C, followed by 10  min incubation at 95°C. The template 
was then amplified for 40 cycles under these conditions: 15  s 
at 95°C and 1 min at 60°C. Samples were normalized using the 
expression of human 18S rRNA. Data were analyzed using the 
Relative Quantification (RQ) Manager Version 1.2.1 (Applied 
Biosystems). Cycle threshold (Ct) values for each target gene 
were calculated and the relative expression was calculated using 
the RQ value via the formula: RQ = 2−∆∆Ct for each target gene, 
and comparing relative expression with that of the 18S rRNA 
constitutive gene product. Assays were conducted twice in trip-
licate. Statistical analysis was performed using GraphPad Prism 
version 6.0 (GraphPad Software). An unpaired two-side t-test 
was used to compare the means of the expressed targets of the 
time points analyzed, using the 2 h time point as the calibrator. 
p Values were computed, and graphs compiled and analyzed.
cell Proliferation assay
PBMCs were re-suspended in serum-free medium containing 
RPMI 1640, Penicillin/Streptomycin and Sodium Pyruvate, and 
stimulated with PHA (Sigma; 11249738001) at a concentration 
of 1 μg/ml and 1 × 105 cells (100 μl) were aliquoted per well in 
a 96-well tissue culture plate. Next, the cells were treated with 
20 μg/ml of ghA, ghB, ghC, or gC1qR in their respective wells. 
Different concentrations of gC1qR (1.25, 2.5, 5, and 10 μg) were 
also coincubated with 20 μg each of gh modules. At the 72  h 
time point, 3H-methy thymidine (MP Biomedicals, USA) was 
added and the plate was pulsed for 16 h. Cells were subsequently 
harvested using a semi-automated cell harvester and the amount 
of 3H-thymidine incorporated into DNA was measured using a 
liquid scintillation counter. Each experiment was conducted in 
triplicates.
resUlTs
expression and Purification of 
recombinant human gc1qr in E. coli 
under Bacteriophage T7 Promoter
Recombinant expression of human gC1qR has been previously 
reported in E. coli as fusion to Glutathione-S-transferase (28). 
FigUre 1 | (a) Expression and purification of recombinant gC1qR. Twelve percent (v/v) SDS-PAGE under reducing conditions. E. coli BL21 (λDE3) strain, 
transformed with plasmid T7-gC1qR and induced with IPTG, overexpressed a ~33 kDa protein (induced) as compared to uninduced cells. Following lysis and 
sonication of the bacterial cells, the overexpressed gC1qR appeared in the soluble fraction sonicate, which was further purified on a Q-Sepharose column.  
(B) Western blotting to show immunoreactivity of recombinant gC1qR: 10 μg of recombinant gC1qR protein was run on a 12% v/v gel and transferred onto a 
nitrocellulose membrane, which was probed with anti-gC1qR polyclonal antibody. BSA was used as a negative control protein.
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Here, we expressed human gC1qR without any fusion partner 
under a strong bacteriophage T7 promoter. E. coli BL21 (λDE3) 
cells, containing the gC1qR construct, expressed a ~33 kDa pro-
tein following IPTG induction, compared to the uninduced cells 
(Figure 1A). The overexpressed protein appeared in the soluble 
fraction following cell lysis and sonication. Recombinant gC1qR 
was subsequently purified using Q-Sepharose. It was step-eluted 
at 0.45  M NaCl and appeared as a single band on SDS-PAGE 
under reducing conditions. The immunoreactivity of the puri-
fied recombinant gC1qR was confirmed by western blot using 
anti-gC1qR polyclonal antibodies that were raised against native 
human gC1qR (Figure 1B).
recombinant gc1qr Binds Differentially 
to the Three globular head Modules of 
human c1q
The recombinant gh modules ghA, ghB, ghC (Figure  2A) and 
their substitution mutants (Figures  2B–D) were expressed as 
MBP fusion proteins and purified on amylose resin. gC1qR 
bound full-length C1q in a dose-dependent manner (Figure 3A). 
When different concentrations of the ghA, ghB, and ghC modules 
were allowed to bind to a constant concentration of gC1qR, all 
modules bound to gC1qR independently in a dose-dependent 
manner (Figure  3B). ghA showed greater binding at 2.5  μg 
when compared with the other two modules, which is consist-
ent with previous findings (29), which implicated ghA to be the 
most important gh region in the C1q–gC1qR interaction. To 
confirm the ELISA results, far-western blot was performed using 
recombinant gC1qR, ghA, ghB, and ghC proteins. Transferring 
gC1qR onto PDVF membrane and probing with gh modules 
revealed independent binding of ghA, ghB, and ghC to gC1qR 
(Figure 3C). Similarly, ghA, ghB, or ghC transferred onto PDVF 
membrane and individually probed with gC1qR confirmed the 
interaction (data not included) that each gh module binds specifi-
cally to gC1qR irrespective of their immobilized orientation on 
the membrane.
arga162 is crucial for c1q–gc1qr 
interaction
Using ELISA, we examined the ability of gC1qR to interact with 
recombinant ghA and its single residue substitution mutants, 
ghA-R162A (i.e., ArgA162Ala) and R162E. Different amounts of 
gC1qR were coated on microtiter wells and incubated with wild-
type ghA, R162A and R162E. As shown in Figure 4A, the substi-
tution of ArgA162 to Ala (R162A) resulted in up to 70% reduction 
in gC1qR binding at 1 μg/ml concentration, with respect to the 
background binding to MBP control protein. Substitution of 
ArgA162 with Glu (R162E) resulted in similar abrogation of bind-
ing when compared to wild-type ghA. To further confirm these 
observations, we carried out a far western blot (Figure 4D). Thus, 
15 μg of gC1qR was transferred onto a PDVF membrane and 
probed with 10 μg each of ghA, R162E and R162A. Figure 4D 
shows a clear band for wild-type ghA. However, probing with 
the mutants revealed a very faint band for R162A while no band 
could be detected on the blot in the case of R162E.
arginine and histidine residues within 
the ghB Module appear important for 
stabilizing c1q–gc1qr interaction
The ability of ghB and its single residue substitution mutants 
(R114Q, R114A, R163A, R163E, T175L, R129A, R129E, and 
H117D) to bind microtiter-coated gC1qR was examined using 
ELISA. The mutant ArgB114 to Gln (R114Q) bound better to gC1qR 
than the wild-type ghB (Figure 4B), suggesting that replacing a 
charged (polar) residue with an uncharged residue can strengthen 
binding between the two proteins. Substituting ArgB114 with Ala, 
FigUre 2 | sDs-Page (12% w/v) under reducing conditions of purified fusion proteins following affinity chromatography. MBP fusion proteins 
containing wild type and mutant globular head modules were purified using an amylose resin column (a). Purified ghA, ghB and ghC (B) purified substitution 
mutants of ghA module; (c) purified mutants of ghB module, R163A, R163E, R114Q, R114A, R129A, R129E, H117D, and T175L; (D) purified ghC, R156Q, 
R156E, and H101A.
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however, was not comparable with R114Q (Figure 4B). Out of all 
the ghB mutants, R114A, R129E, R163E, and H117D showed con-
siderable reduction in binding. Thus, substituting arginine with 
glutamine had an adverse effect on the ghB–gC1qR interaction. 
Substituting His to Asp reduced ghB affinity for gC1qR by nearly 
60%, which suggests that HisB117 is very important for gC1qR 
binding. When comparing all the ghB substitution mutants, it 
was evident that the most significant effect was caused by the 
substitution of arginine to glutamine, suggesting that ArgB163 is 
crucial for gC1qR binding to C1q (Figure 4B). Similar observa-
tions were noted for the ghC mutants (Figure 4C).
Microscopy studies
Since we established that ghA, ghB, and ghC individually bind to 
gC1qR, we performed microscopic studies to determine whether 
the gh’s of C1q can colocalize with gC1qR on the surface of 
PBMCs. We first verified the interaction by identifying gC1qR 
on the surface using polyclonal antibodies against gC1qR (gC1qR 
in Figure  5). Incubation of the gh modules and probing with 
anti-MBP monoclonal antibodies showed the gh’s bound on the 
surface of PBMCS with partial colocalization to gC1qR (Figure 5, 
arrows in merged images).
Transcriptional expression of gc1qr 
and c1q in adherent Monocytes
To examine a possible correlation between the temporal pattern 
of expression of C1q and gC1qR, qPCR analysis was performed 
in view of the fact that adherent monocytes upregulate C1q 
expression, a situation that mimics inflammation. In addition, 
the expression of C1q and gC1qR in the adherent monocytes was 
also assessed with and without LPS challenge (acting as a pro-
inflammatory stimulus). C1q-RNA expression increased mark-
edly in monocytes during adherence, peaking at 72 h with a log10 
3.5-fold difference compared to 2 h after adherence (Figure 6A). 
In contrast, incubation with LPS had a suppressive effect on C1q 
expression. There was also an increase in the gC1qR expression 
during monocyte adherence, with the pattern of expression 
appearing to be biphasic in nature with the peaks observed at 
24 and 72 h (Figure 6B). In contrast to C1q, the presence of LPS 
elevated the expression of gC1qR, peaking at 24  h adherence, 
FigUre 3 | (a) ELISA to show binding of gC1qR to C1q: microtiter wells, coated with different concentrations of human C1q (5, 2.5, 1.25, and 0.625 μg/well), were 
incubated with 2.5 μg of gC1qR. Bound gC1qR was detected by anti-gC1qR polyclonal antibody followed by Protein A-HRP conjugate. MBP was used as a 
negative control protein. (B) ELISA to assess interaction of gC1qR with ghA, ghB, and ghC modules. gC1qR (1 μg/well in 100 μl) was coated on microtiter wells and 
then incubated with various concentrations of wild type of ghA, ghB, and ghC. MBP was used as a negative control. Following washing, bound protein was 
detected using anti-MBP monoclonal antibody and goat anti-mouse IgG HRP conjugate. (c) Far-western blot analysis to show ghA, ghB, and ghC binding to 
gC1qR: 15 μg of gC1qR was first run on the SDS-PAGE under reducing conditions, transferred onto a PDVF membrane and then probed with 10 μg each of ghA, 
ghB, and ghC. Lanes 1 through 3 show interaction of gC1qR with ghA, ghB, and ghC, respectively.
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more than twice the level observed without LPS. These results 
are consistent with an earlier study, showing enhancement of 
gC1qR surface expression on endothelial cells after 24  h (30). 
However, LPS seems to cause enhancement of gC1qR expression 
rather than inhibition, unlike C1q (Figure 6A), suggesting that 
gC1qR on its own may have a regulatory role in LPS-mediated 
inflammation.
gha, ghB, ghc, and gc1qr inhibit  
Pha-stimulated Proliferation of PBMcs
Since C1q is known to have anti-proliferative effect on T cells 
(25), we examined if this inhibition is mediated through the gC1q 
domain. ghA, ghB, and ghC individually were able to inhibit PHA-
stimulated proliferation of PBMCs (Figure 7A), as measured by 
thymidine uptake. The gh modules inhibited proliferation by 
>threefold when compared to PBMCs stimulated with PHA 
alone and MBP control. Next, we sought to determine whether 
the addition of different concentration of gC1qR to a fixed gh con-
centration would further inhibit proliferation. Figure 7B shows 
an inhibitory dose response for each gh module with the addition 
of gC1qR at different concentrations. The addition of 1.25 μg of 
gC1qR increased ghA and ghC mediated anti-proliferative effects 
by 40% (Figure 7B).
DiscUssiOn
C1q, as a charge pattern recognition protein, is able to bind to 
a range of self and non-self-ligands through its heterotrimeric 
FigUre 4 | elisa to assess interaction between gc1qr and gh substitution mutants. Microtiter wells were coated with different quantities (0.25, 0.5, and 
1 μg/well) of gC1qR. After blocking and washing, the wells were incubated with 2.5 μg/well of (a) ghA, R162A and R162E; (B) ghB, R114A, R114Q, R163A, 
R163E, R129A, R129E, T175L, and H117D; and (c) ghC, for 90 min at 37°C and 90 min at 4°C. Bound proteins were detected with anti-MBP monoclonal antibody 
followed by goat anti-mouse IgG–HRP conjugate. Data are representative of three experiments. (D) Ligand blot to show binding of ghA mutants R162A and R162E 
to gC1qR: PVDF membrane strips containing gC1qR were reacted with ghA, R162A and R162E, and then probed with anti-MBP monoclonal antibody followed by 
goat anti-mouse IgG–HRP.
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gC1q domain (5, 31). The gC1q domain is also found in a 
range of non-complement proteins (22, 32, 33), including col-
lagen VIII, precerebellin, and multimerin (2, 32–37). The crystal 
structure analysis of the gC1q domain shows a sphere-shaped, 
heterotrimeric arrangement with the N- and C-terminal ends of 
each domain residing at the base of the trimer (5). The crystal 
structure has also identified an exposed Ca2+ ion located at the 
apex; this has been considered important in the binding of gC1q 
to its ligands.
Out of several candidate receptors for C1q, calreticulin (cC1qR) 
binds to the collagen region of C1q, while gC1qR interacts with 
the gC1q domain (2, 13). However, the nature and the context of 
interaction between C1q and gC1qR have not been examined. 
Previous studies, using ligand blot analysis with C1q run under 
reducing conditions, have shown that gC1qR binds predomi-
nantly to the A chain and moderately to the C chain of C1q with 
the A chain Arg residue at positions 162 being critical for binding 
(28). The availability of the recombinant forms of ghA, ghB, and 
ghC (18) and their substitution mutants (22) gave us with the 
opportunity to fully explore the gC1q–gC1qR interaction.
Previous studies have shown that gC1qR inhibits aggregated 
IgG-mediated complement activation by binding to the gC1q site 
on C1q, thereby preventing IgG from binding to the gh’s (28), 
suggesting that the binding sites for gC1qR and IgG on C1q may 
be identical or at least overlapping. It has also been shown that 
one of the IgG binding sites resides on Arg162 of the A chain (38), 
consistent with the mutational studies where the mutant R162E 
showed reduced the ability of C1q to bind to IgG by 35% (22). 
FigUre 5 | interaction of gha, ghB, and ghc with monocyte/macrophages. PMBCs (1 × 106) were seeded on 13 mm coverslips and incubated in complete 
RPMI 1640 medium for 2 weeks at 37°C in 5% CO2 incubator. Cells were treated with 10 μg of each globular head module and incubated with serum-free RPMI 
1640 medium for 1 h at 37°C. After washing with PBS, cells were fixed with 4% PFA, permeabilzed with Triton X-100, and probed with anti-gC1qR polyclonal 
antibody and anti-MBP monoclonal antibody to reveal gC1qR and bound globular head modules, respectively. Cells were washed and treated with Alexa Fluor 488 
conjugated secondary goat anti-rabbit antibody and Alexa Fluor 647 conjugated secondary donkey anti-mouse antibody and the nucleus was stained with Hoechst 
33342. Cells were then examined under Leica fluorescence microscope with 40× magnification. In the merged images gC1qR is green; globular heads are red; and 
nucleus is blue. Arrows point to bound globular heads with colocalization of globular heads and gC1qR seen in orange in the merged images. Scale bars: 10 μm.
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The importance of arginine residues in the ligand recognition 
of gC1q domain is consistent with the observation in this study 
(Figure 3B). Ghebrehiwet et al. have previously shown that the 
Arg162 in C1q A chain is significant in gC1qR binding (39). A pep-
tide corresponding to the A chain with the Arg residue at position 
162 substituted to Glu showed no binding to gC1qR. It has also 
been noted that residues 154–165 of the A chain are implicated 
in IgG binding (38), and inhibition studies have demonstrated 
that forming a complex between gC1qR and C1q prevented C1q 
binding to SRBCs, and hence, complement activation. These 
data are consistent with Figure 4A, which shows that substitu-
tion of the arginine residue in ghA reduces its binding to gC1qR 
considerably. We further examined the contributions of Arg114, 
Arg163, and His117 (of ghB) and Arg156 (of ghC) to the C1q–gC1qR 
FigUre 7 | anti-proliferative effects of gha, ghB, and ghc modules. 
Human PBMCs from healthy individuals were stimulated with PHA (1 μg/ml) 
for 3 days with or without recombinant gC1qR (1.25, 2.5, 5, 10, and 20 μg/
ml), ghA, ghB, or ghC (20 μg/ml) followed by a 16 h pulse in the presence of 
tritiated methyl thymidine ([3H]TdR). Each experiment was carried out in 
triplicates. (a) Each of ghA, ghB, ghC, and gC1qR inhibited PHA-stimulated 
proliferation of PBMCs; (B) ghA, ghB, and ghC coincubated with gC1qR 
inhibit PHA-stimulated proliferation of PBMCs.
FigUre 6 | expression of c1q (a) and gc1qr (B) by adherent human 
monocytes in vitro. The expression of C1q and gC1qR was measured 
using real-time qPCR and the data were normalized via 18S rRNA gene 
expression as a control. Relative expression (RQ) was calculated by using the 
2 h time point as the calibrator. The RQ value was calculated using the 
formula: RQ = 2−∆∆Ct. Assays were conducted twice in triplicates. Error bars 
represent ±SEM. A two-side t-test was performed on the data. All samples 
showed significant expression compared to the calibrator (p ≤ 0.01), except 
where noted: *0.01 < p < 0.05; ns: not significant (p ≥ 0.05). LPS was added 
to cultures at a 20 ng/μl concentration.
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interaction by substituting them with either neutral or negatively 
charged residues. Thus, the substitution of Arg to glutamine at 
amino acid 114 position of the B chain showed a much better 
binding to gC1qR than the wild-type ghB. The observation that a 
substitution mutant interacts better than the wild type is of great 
interest, offering an opportunity to neutralize the involvement 
of gC1qR in infection and inflammation. Experiments involving 
chemical modification have shown Arg11 of the B chain to be an 
important residue in IgG binding (38). 
The qPCR-based mRNA expression studies appeared to 
suggest that both C1q and gC1qR are upregulated in adherent 
monocytes in a biphasic manner. It is likely that the two proteins 
are coexpressed under pro-inflammatory conditions and can 
regulate each other’s functions, or may have distinct functions 
by recognizing unique self and non-self-molecular targets. When 
LPS was used in the assay, the expression of C1q was down-
regulated, but gC1qR levels were upregulated, suggesting that 
C1q and gC1qR may have distinct roles in LPS-mediated immune 
response that are independent of each other.
Since C1q is known to exert an anti-proliferative effect on 
T cells (25), it was of interest to examine if individual gh modules 
were also anti-proliferative and if the addition of gC1qR in the 
assay could modulate this effect. Here, we show that ghA, ghB, 
and ghC modules also possess anti-proliferative properties of C1q 
(Figure 7). gC1qR had an additive effect on the anti-proliferative 
effects of gh modules in a dose-dependent manner (Figure 7A). 
The engagement of C1q with gC1qR, expressed on CD4+ and 
CD8+ T cells, is known to suppress cell proliferation (25). 
Therefore, further attenuation of cell proliferation by gC1qR 
is likely to be mutually beneficial for the immune regulation. 
Previously, it was thought that the “full-length” gC1qR (residues 
1–282) was mostly resident in the mitochondria, which is then 
cleaved off to release the “mature form” (residues 74–282) 
expressed on the cell surface (16). However, subsequent studies 
have shown that the membrane associated-form is, in fact, the 
full-length gC1qR from which the mature form consisting of 
residues 74–282 is cleaved off and released as a soluble form into 
the pericellular milieu. On endothelial cells, the soluble form has 
been shown to induce bradykinin 1 receptor (B1R) expression by 
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binding to surface bound fibrinogen in an autocrine manner (40). 
Thus, the soluble gC1qR is capable of binding to immune cells 
and modulating various cellular immune responses, including 
cell proliferation. The anti-proliferative activity of gC1qR has 
also been demonstrated through the HCV core protein, which 
binds gC1qR on T cells and inhibits their growth, highlighting 
a role for gC1qR in host immune evasion (41). It is likely that 
the interaction of C1q with gC1qR provides a negative growth 
signal, which interferes with normal cell proliferation. This could 
prove useful in developing targeted therapies where uncontrolled 
proliferation of immune cells is a critical pathological issue.
The expression of gC1qR has been detected in several cellular 
compartments such as mitochondria (42), nucleus (43), and on 
the cell surface of neutrophils, mast cells, T and B lymphocytes, 
endothelial cells, monocytes, and platelets (44–48). However, 
since gC1qR is devoid of a transmembrane domain, it has been 
proposed to exert its signal across the membrane through a 
docking/signal interaction with CD44 (49). We carried out 
microscopy studies to investigate the colocalization of gC1qR 
with the gh modules on the cell surface of monocyte-derived 
macrophages, which revealed gC1qR’s presence on the cell surface 
(Figure 5). We could also observe colocalization of individual gh 
with gC1qR. Although C1q has been shown to bind to residues 
76–93 of gC1qR, it appears that there could be additional bind-
ing sites on gC1qR (50) involving residues 144–162. This paper 
together with the other studies, establishing the importance of 
C1q–gC1qR interaction in disease models, where complement 
activation is a critical factor in disease progression such as ath-
erosclerosis and Alzheimer’s disease, could be relevant for the 
development of novel therapeutic strategies.
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